PENS Co., Ltd. is developing various biomaterials that can be used for various conditions like osteoporosis, height growth, kidney function, cardiopulmonary function, immunity, etc. The research-based startup is currently selecting and analyzing over 20 indicator materials for the purpose. Biomaterials or a substance made to fit in with biological systems are being widely used for medicinal treatment or therapies. Many science-based companies are looking at developing biomaterials for various ailments and conditions.
The global biomaterial market is forecasted to register a combined growth rate of 13.69%. Many factors, including the popularity of implant devices, the plastic surgery market, biomaterial usage in wound care, etc., are driving the market’s growth. It has been observed that Korean start-ups have been performing admirably in the biomaterial segment.
PENS Co has focused its research activities on primarily these two health issues and already has two domestic patents in its kitty even as it waits for its global patenting applications to be approved. For the products targeting stunted growth, a high percentage of the indigenous Korean herb Humulus japonicas has been found as a component. The Humulus Japonicus is an active substance that promotes cell division and tissue growth, and its use as a health supplement has been patented.
International Journals are already expected to publish two scientific journals penned by PENS Co research teams. The journals discuss Humulus japonicas’ effect on total bone growth volume in laboratory rats and Humulus japonicas’ reaction on the IGF 1 levels of rodents.
PENS’ two SCI papers based on the results of cell and animal experiments related to height growth will be published in international journals in the second half of 2020:
- ‘A Mixture of Humulus japonicus Increases Longitudinal Bone Growth Rate in Sprague Dawley Rats’ (JOURNAL OF NUTRIENTS)
- ‘Effect of Humulus japonicus complex on Bone Growth and IGF-1 levels in Rats
KIM Hong Sik, PENS Founder, is a Ph.D. holder who has worked with prestigious concerns like the Korea Food Research Institute, National Institute of Health, etc. He has significant exposure in public health and has experience in developing a well-received Malaria diagnostic kit. PENS Co has many well-known researchers on board as advisors and core members. The start-up is poised to formally launch its prototype in 2020 before pushing in the China Market. PENS Co also targets south Asia, Europe, Japan, South America, and Australia.
